Queue

Cancers in the set

Each cancer resolves to an Open Targets id before a cycle starts. Click a row for the id, the reason it is in the set, and any finished records.

• Melanoma

  19 Aug 2026: first positive Phase 3 individualized mRNA neoantigen therapy (intismeran + pembrolizumab) in resected IIB-IV melanoma. Can the gauntlet treat that as known fact, not a new discovery?

  hot
• PDAC

  Five-year survival still ~13%. Dense stroma, low T-cell infiltrate, KRAS-locked. The disease that measures whether the agents can be honest about failure.

  hard
• GBM

  Blood-brain barrier, wild heterogeneity. Almost every Phase 3 in recurrent GBM has failed.

  hard
• TNBC

  No ER/PR/HER2 handle. Immunotherapy helps a subset. The rest is still cytotoxic guesswork.

  unsolved
• NSCLC

  Oncogene-addicted slices keep getting solved (EGFR, ALK, MET). The remaining wild-type / STK11 / KEAP1 tumors are the real queue.

  unsolved
• HGSOC

  PARP inhibitors work while HRD lasts. Platinum resistance is the wall.

  unsolved
• AML

  Many targeted slices (FLT3, IDH, menin). Relapse biology and TP53-mutant disease still eat the survival curve.

  unsolved
• CML

  Solved. Imatinib / dasatinib / nilotinib against BCR::ABL1. If the gauntlet cannot reconstruct that from the graph, do not trust it on PDAC.

  control
• thyroid

  Queued by a human. Must resolve against Open Targets before it is evidence.

  unsolved
• skin

  Queued by a human. Must resolve against Open Targets before it is evidence.

  unsolved
• liver

  Queued by a human. Must resolve against Open Targets before it is evidence.

  unsolved
• lung

  Queued by a human. Must resolve against Open Targets before it is evidence.

  unsolved